Aripiprazole
Brand names: Abilify Asimtufii, Abilify Maintena, Aripiprazole Odt, Abilify, Abilify Mycite, Aripiprazole
Part of: Antipsychotics
At a glance
- Medicare prescriptions, 2024
- 3,493,985
- Medicare drug cost
- $739.8M
- Average cost per prescription
- $212
- Clinicians who prescribed it
- 74,359
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ABILIFY MAINTENA (aripiprazole) is indicated: for the treatment of schizophrenia in adults for maintenance monotherapy treatment of bipolar I disorder in adults
From the FDA-approved prescribing information (label dated March 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 31.1%
- Psychiatric Nurse Practitioners 27.0%
- Family Medicine 11.8%
- Nurse Practitioners 11.1%
- Internal Medicine 8.2%
- Physician Assistants 5.2%
- Child & Adolescent Psychiatry 1.6%
- Geriatric Medicine 1.1%
- Neurology 0.7%
- General Practice 0.5%
- Hospitalist 0.3%
- Addiction Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 22% from 2019 to 2024.
Biggest change by state since 2019
- Utah +58%
- Arkansas +51%
- Louisiana +49%
- Nevada +47%
- New Hampshire +41%
- California (smallest change) +3%
- District of Columbia (smallest change) +6%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Accord Healthcare, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | green rectangle tablet, 8 mm | A2 |
| 5 mg | blue rectangle tablet, 8 mm | A5 |
| 10 mg | pink rectangle tablet, 8 mm | A10 |
| 15 mg | yellow round tablet, 7 mm | A15 |
| 20 mg | white round tablet, 8 mm | A20 |
| 30 mg | pink round tablet, 9 mm | A30 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 8 mm | 65 H |
Major Pharmaceuticals
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | green rectangle tablet, 8 mm | AN896 2 |
| 5 mg | blue rectangle tablet, 8 mm | AN897 5 |
| 10 mg | pink rectangle tablet, 8 mm | AN898 10 |
| 15 mg | yellow round tablet, 6 mm | AN899 15 |
| 20 mg | white round tablet, 8 mm | AN901 20 |
| 30 mg | pink round tablet, 9 mm | AN902 30 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | blue rectangle tablet, 8 mm | I 95 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $3.5M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Otsuka America Pharmaceutical, Inc. $3.2M
- Lundbeck LLC $164,139
- H. Lundbeck A S $53,330
- Otsuka Pharmaceutical Development & Commercialization, Inc. $33,862
- E.r. Squibb & Sons, L.l.c. $832
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
7 recalls since 2020
- May 2026 · Ajanta Pharma USA Inc · Class II
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg. - Aug 2025 · Ascend Laboratories, LLC · Class II
Superpotent drug - Apr 2024 · Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. · Class III
Cross Contamination with Other Products - Mar 2023 · Ascend Laboratories, LLC · Class II
Out of specification (OOS) for Spectroscopic Identification test by IR. - Feb 2023 · Accord Healthcare, Inc. · Class II
CGMP Deviations: recalling drug products following an FDA inspection. - Jan 2022 · Cardinal Healthcare · Class II
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. - Jun 2020 · Alembic Pharmaceuticals Limited · Class II
Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.